

East Lancashire Hospitals NHS Trust – NIHR performance in delivering research – 01.01.2015 to 31.03.2015

Research Ethics Committee Reference Number	Name of Trial	Target number of patients available	Target number of patients	Date Agreed to recruit target number of patients available	Date Agreed to recruit target number of patients	Trial Status	Target met within the agreed time	Comments
14/SC/0065	CANVAS-R: A randomised multicentre, double-blind,parallel, placebo-controlled study of the effects of Canagliflozin on renal endpoints in adult subjects with type 2 diabetes mellitus	Available	12	Available	30/06/2017	Closed - In Follow Up	Y	Sponsor closed screening on 20.03.2015 to avoid over enrolment into the study
13/LO/1438	User assessment of the NovaLife one-piece skin barrier	Available	4	Available	30/06/2014	Closed - Follow Up Complete	Y	
13/LO/0528	PIONEER: An Open-label, Randomised, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention	Available	1	Available	30/08/2015	Open	N/A	Sponsor extended recruitment period for our site. Target recruitment date is now 30/08/2015
14/NW/1462	TM Reverse: Prospective Post Market Clinical Follow-Up Study of the Zimmer Trabecular Metal Reverse Shoulder System	Available	40	Available	30/06/2026	Open	N/A	
13/LO/1277	SPARTAN: A multi-centre, randomised, double blind, placebo-controlled, phase III of ARN-509 in men with non-metastatic (MO) castration-resistant prostate cancer	Available	3	Available	30/06/2016	Open	N/A	
14/SC/1161	Prospective single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients	Available	64	Available	30/11/2017	Open	N/A	
14/NE/1214	A randomised, open-label, multicentre, phase 2 trial comparing veliparib plus carboplatin and paclitaxel versus investigator's choice of standard chemotherapy in subjects receiving first cytotoxic chemotherapy for metastatic or advanced non-squamous non-small cell lung cancer (NSCLC) and who are current or former smokers	Available	7	Available	29/02/2016	Open	N/A	